ENPP2 and neoplasm: Pre-clinical investigations in both cell cultures and murine tumor models have provided considerable support for inhibitors against the ATX-LPAR-LPP pathway, some of which, especially against ATX and the LPARs, are currently in clinical trials [4,27,28,29,30,31].